• Aptamer Group Signs Material Agreement with Genetic Medicines Company 12/15/2023
• Aptamer Group and Neuro-Bio Partner to Develop an Alzheimer’s Disease Diagnostic Test 6/15/2023
• Aptamer Launches Optimer®-Fc as a New Reagent Solution for Immunohistochemistry 3/23/2023
• Aptamer Group Partner with BaseCure Therapeutics to Develop New Targeted Gene Therapies 2/1/2023
• Aptamer Group Announces New Deals to Support Novel Therapies and Improved Assays 12/5/2022
• Aptamer Group Signs Deal with Flip Gene Therapeutics to Support the Development of Inducib... 6/16/2022
• Aptamer Group and PinotBio Extend Collaboration for the Development of Optimer®-drug ... 5/26/2022
• Aptamer’s Leadership and Technical Achievements are Recognised 4/6/2022
• Optimer® Diagnostic Reagent Detects Omicron Variant 1/20/2022
• Aptamer Group and DeepVerge Expand Partnership for Optimer®-enabled Wastewater Monito... 11/5/2021
• Aptamer Group and Bio-Works Technologies Partner to Enable Improved Solutions for Gene The... 8/26/2021
• Aptamer Group and WuXi AppTec Research Service Division Collaborate to Identify New Optime... 7/23/2021
• Aptamer Group Partners with Top Five Global Pharmaceutical Company to Support Innovative V... 7/15/2021
• Aptamer and PinotBio Collaborate to Develop New Therapeutic Drug Conjugates 6/4/2021
• Aptamer Group Collaborates with World-leading Pharmaceutical Company to Evaluate Optimer T... 6/3/2021
• Aptamer Group and Mologic Enter Commercial Partnership to Develop Aptamer-based SARS-CoV-2... 3/19/2021